Document:

Exhibit 10.22(e) 

FOURTEENTH AMENDMENT TO
LEASE 

     THIS
FOURTEENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this
30th
day of November, 2007, by and between BMR-LANDMARK AT EASTVIEW LLC, a Delaware
limited liability company (“Landlord”), as successor-in-interest
to Keren Limited Partnership (“Original
Landlord”), and EMISPHERE TECHNOLOGIES, INC.,
a Delaware corporation (“Tenant”).

RECITALS 

     A. WHEREAS,
Original Landlord and Tenant entered into that certain Lease dated as of March
31, 1997, as amended by that certain Amendment of Lease dated as of January 31,
1999; that certain Second Amendment of Lease dated as of July 31, 2000; that
certain Third Amendment of Lease dated as of July 31, 2000; that certain Fourth
Amendment of Lease dated as of May 30, 2001; that certain Fifth Amendment of
Lease dated as of February 11, 2002; that certain Sixth Amendment of Lease dated
as of January 24, 2003; that certain Seventh Amendment of Lease dated as of
September 23, 2003; that certain Eighth Amendment to Lease dated as of August
22, 2006; that certain Ninth Amendment to Lease dated as of September 26, 2006;
that certain Tenth Amendment to Lease dated as of October 31, 2006; that certain
Eleventh Amendment to Lease dated as of November 30, 2006; that certain Twelfth
Amendment to Lease dated as of February 7, 2007; and that certain Thirteenth
Amendment to Lease dated as of May 31, 2007 (collectively, and as the same may
have been further amended, supplemented or otherwise modified from time to time,
the “Lease”), whereby Tenant leases certain premises (the “Premises”) from Landlord in
two of the buildings at 765 and 777 Old Saw Mill River Road in Tarrytown, New
York (the “Buildings”); 

     B.
WHEREAS, Tenant desires to surrender a portion of
the Premises; and 

     C. WHEREAS,
Landlord and Tenant desire to modify and amend the Lease only in the respects
and on the conditions hereinafter stated. 

AGREEMENT 

     NOW,
THEREFORE, Landlord and Tenant, in consideration of the mutual promises
contained herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound,
agree as follows: 

     1. Definitions. For purposes of this
Amendment, capitalized terms shall have the meanings ascribed to them in the
Lease unless otherwise defined herein. 

     2. Surrender of Premises. Tenant shall,
no later than November 30, 2007 (the “Surrender Date”), surrender to
Landlord approximately six thousand five hundred twenty-seven (6,527) rentable
square feet of the Premises, as shown on Exhibit A attached hereto (the
“Surrendered Premises”), in the condition required by the Lease; provided, however, that
Tenant may leave the personal property listed on
Exhibit B
hereto in the Surrendered Premises after the Surrender Date. 

     3. Fixed
Rent. From and after the Surrender Date,
Tenant’s Fixed Rent shall be reduced by Fourteen Thousand Four Hundred Thirteen
and 79/100 Dollars ($14,413.79) per month (equal to One Hundred Seventy-Two
Thousand Nine Hundred Sixty-Five and 50/100 Dollars ($172,965.50) per year).
From and after the Surrender Date, Tenant’s Fixed Rent shall equal One Hundred
Seventy-Seven Thousand Seven Hundred Fifty-Nine and 79/100 Dollars ($177,759.79)
per month (equal to Two Million One Hundred Thirty-Three Thousand One Hundred
Seventeen and 50/100 Dollars ($2,133,117.50) per year). 

     4. Tenant’s Proportionate Share. Tenant’s
Proportionate Share shall mean, from and after the Surrender Date, ten and
seventy-one hundredths percent (10.71%). 

     5. Notices. The addresses for notices to
Landlord and Tenant as set forth in the Lease are hereby changed to the
following: 

For
Landlord: 

     BMR-Landmark at Eastview LLC
     17140 Bernardo Center Drive, Suite
222
     San Diego, California
92128
     Attn: General
Counsel/Real Estate

For
Tenant:

     Emisphere Technologies,
Inc.
     765 Old Saw Mill River
Road
     Tarrytown, New York
10591
     Attention: Paul Lubetkin, Esq., Vice
President and General Counsel 

     6. Broker. Tenant represents and warrants
that it has not dealt with any broker or agent in the negotiation for or the
obtaining of this Amendment and agrees to indemnify, defend and hold Landlord
harmless from any and all cost or liability for compensation claimed by any
broker or agent employed or engaged by it or claiming to have been employed or
engaged by it.

     7. No
Default. Tenant represents, warrants and
covenants that, to the best of Tenant’s knowledge, Landlord and Tenant are not
in default of any of their respective obligations under the Lease and no event
has occurred that, with the passage of time or the giving of notice (or both)
would constitute a default by either Landlord or Tenant thereunder. 

     8. Effect
of Amendment. Except as modified by this
Amendment, the Lease and all the covenants, agreements, terms, provisions and
conditions thereof shall remain in full force and effect and are hereby ratified
and affirmed. The covenants, agreements, terms, provisions and conditions
contained in this Amendment shall bind and inure to the benefit of the parties
hereto and their respective successors and, except as otherwise provided in the
Lease, their respective assigns. In the event of any conflict between the terms
contained in this Amendment and the Lease, the
terms herein contained shall supersede and control the obligations and
liabilities of the parties. From and after the date hereof, the term “Lease” as
used in the Lease shall mean the Lease, as modified by this Amendment.

     9. Miscellaneous. This Amendment becomes
effective only upon execution and delivery hereof by Landlord and Tenant. The
captions of the paragraphs and subparagraphs in this Amendment are inserted and
included solely for convenience and shall not be considered or given any effect
in construing the provisions hereof. All exhibits hereto are incorporated herein
by reference. 

     10. Counterparts. This Amendment may be
executed in one or more counterparts that, when taken together, shall constitute
one original. 

[REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK]

     IN
WITNESS WHEREOF, Landlord and Tenant have hereunto set their hands as of the
date and year first above written, and acknowledge that they possess the
requisite authority to enter into this transaction and to execute this
Amendment. 

LANDLORD: 

BMR-LANDMARK AT EASTVIEW LLC,
a
Delaware limited liability company
 

	By: 
    	/s/ Gary A.
      Kreitzer  
	Name:  	Gary A.
      Kreitzer  
	Title:  	Executive
      V.P.  

TENANT: 

EMISPHERE TECHNOLOGIES, INC.,
a
Delaware corporation
 

	By: 
    	/s/ Paul
      Lubetkin  
	Name:  	Paul
      Lubetkin  
	Title:  	Vice
      President and General Counsel  

EXHIBIT A 

SURRENDERED
PREMISES 

[See attached]

 

 

 

 

 

 

 

 

 

 

EXHIBIT B 

PERSONAL
PROPERTYExhibit 10.47 

EMISPHERE TECHNOLOGIES, INC. —
MANNKIND CORPORATION
PATENT PURCHASE AGREEMENT

     This
Patent Purchase Agreement (“Agreement”) is entered into by and
between Emisphere Technologies, Inc. (“Emisphere”) a Delaware corporation,
having a business address at 240 Cedar Knolls Road, Cedar Knolls, New Jersey
07927, and MannKind Corporation, a Delaware corporation having a business
address at 28903 North Avenue Paine, Valencia, California 91355
(“MannKind”). 

RECITALS 

     WHEREAS, Emisphere owns the Assigned
Patents (as defined below); 

     WHEREAS,
MannKind desires to purchase the Assigned Patents from Emisphere; 

     NOW, THEREFORE; the parties agree as
follows:

1. DEFINITIONS

     1.1 Definitions. For purposes of this
Agreement, the following words, terms and phrases shall have the meanings
assigned to them in this Section 1.1, unless specifically otherwise stated.

          1.1.1 “Affiliate” means, with respect to a party, a corporation, company or other entity
that controls, is under common control or is controlled by such party. For
purposes hereof, “control” means the direct or indirect ownership of over 50% of
outstanding voting securities or shares of an entity; provided that a
corporation, company or other entity shall be deemed to be an Affiliate (and be
subject to the terms of this Agreement) only for so long as such control
continues. 

          1.1.2 “Assigned Patents” means (a) those patents and patent applications specifically
set forth in Schedule 1; (b) all rights of priority in any of the foregoing
patents and patent applications, and any divisional, continuation,
continuation-in-part, substitute, request for continued examination, renewal,
reexamination, or reissue of any of the foregoing patents and patent
applications which have been or may be filed in the United States or elsewhere
in the world; and (c) any patents which may be granted on any of the foregoing
applications anywhere in the world. No other patents or patent applications are
included in the Assigned Patents. 

          1.1.3 “Effective Date” means the date this Agreement has been executed by both
parties, as evidenced by the latter of the dates indicated in the signature
block. 

          1.1.4 “FDA” means the U.S. Food and Drug
Administration. 

2. TRANSFER AND ASSIGNMENT

     2.1 Patent
Assignment. Emisphere hereby irrevocably
transfers and assigns to MannKind the entire right, title and interest in the
Assigned Patents, including the right to sue for any past infringement by any
third party. The Parties acknowledge that, as of the Effective Date, MannKind is
the sole owner of the Assigned Patents. Emisphere shall execute and deliver to
MannKind the pro forma patent assignment set forth in Exhibit 1, dated as of the
Effective Date, which MannKind will reasonably promptly record at the U.S.
Patent and Trademark Office (“USPTO”). 

     2.2 Perfection of Rights. Emisphere agrees
to take any steps specified by Mannkind in writing (at MannKind’s expense)
necessary to perfect MannKind’s title or rights to any subject matter intended
to be vested in MannKind pursuant to this Agreement, including but not limited
to executing oaths, assignments, powers of attorney, applications, and other
papers necessary or desirable to fully secure to MannKind the rights, titles and
interests conveyed herein. 

     2.3 No
Other Rights. Other than as expressly stated
herein, no rights or licenses are granted or may be construed under this
Agreement, expressly, by implication, inducement, estoppel or otherwise, with
respect to any intellectual property rights owned by or controlled by Emisphere
or its Affiliates or by MannKind or its Affiliates. 

3. CONSIDERATION

     3.1 Patent
Purchase Fee. The consideration for the
Assigned Patents is Two Million, Five Hundred Thousand Dollars ($2,500,000.00),
payable as specified below. 

     3.2 Payment at Signing. MannKind agrees
to pay Emisphere One Million, Five Hundred Thousand Dollars ($1,500,000.00)
within three business days of the Effective Date. 

     3.3 Payment at Time of FDA Filing. MannKind agrees to pay Emisphere Five Hundred Thousand Dollars ($500,000)
within five business days of the first to occur of the following: (a) the date
that the FDA accepts MannKind’s filing of a New Drug Application for its
Technosphere® Insulin product and an associated pulmonary delivery system with
the FDA, or (b) June 30, 2009. 

     3.4 Payment at Time of FDA Approval. MannKind agrees to pay Emisphere Five Hundred Thousand Dollars ($500,000)
within five business days of the first to occur of the following: (a) the date
that MannKind obtains final approval from the FDA of the application described
in Section 3.3 above, or (b) September 30, 2010. 

     3.5 Taxes. The payments described above do
not include any taxes (including any excise, sales, use, value added,
withholding, and similar taxes), customs duties, tariffs or license fees, and
payments to Emisphere are payable in full without reduction for any such taxes,
duties, tariffs or fees. MannKind shall be responsible for and shall indemnify
Emisphere for any and all taxes, customs duties, tariffs and license fees paid
or payable, however designated, levied, or based on payments to Emisphere
hereunder, but excluding United States federal, state and local taxes based on
Emisphere’s net income.

If Emisphere has the legal obligation
to pay or collect any such taxes, duties, tariffs, fees or other charges,
excluding taxes on the net income of Emisphere, the appropriate amount shall be
invoiced to MannKind and paid by MannKind within thirty (30) days after receipt
of Emisphere’s invoice, unless MannKind provides Emisphere with a valid tax or
other exemption certificate issued or authorized by the appropriate authority or
provides Emisphere such other evidence requested by Emisphere to establish such
exemption. MannKind shall provide Emisphere or its designee with official
receipts issued by the appropriate taxing or other authority or such other
evidence as is reasonably requested by Emisphere to establish that such taxes,
duties, tariffs, fees or charges have been paid. 

4. PATENT PROSECUTION,
ENFORCEMENT AND DEFENSE 

     4.1 Deliverables. On the Effective Date,
Emisphere shall (a) deliver to MannKind docket reports from Emisphere’s
intellectual property in-house and/or external counsel (the latter,
“Legacy IP Counsel”) for the Assigned Patents; and (b) instruct its in-house and/or Legacy
IP Counsel to make accessible to MannKind copies of all correspondence from the
USPTO or any other patent office relating to the Assigned Patents.

     4.2 Assigned Intellectual Property Rights.
MannKind assumes responsibility for all prosecution, maintenance and enforcement
of the Assigned Patents at its sole discretion, including retaining replacement
counsel therefor. MannKind acknowledges that Legacy IP Counsel is not required
to undertake or continue any prosecution of the Assigned Patents, but may do so
upon mutual agreement with MannKind. 

     4.3 Patent
Prosecution Assistance. Emisphere shall
provide MannKind with patent prosecution assistance pursuant to Section 4.1.

     4.4 Patent
Enforcement/Defense Assistance. If mutually
agreed between the parties, Emisphere may provide MannKind with patent
enforcement and/or defense assistance pursuant to Section 4.2. 

5. REPRESENTATIONS,
WARRANTIES AND COVENANTS 

     5.1 Mutual
Representations and Warranties. Each party
represents and warrants to the other that: 

          5.1.1 It has all requisite corporate power to enter into this Agreement and to
carry out the transactions contemplated by this Agreement; 

          5.1.2 The execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated by this Agreement have been duly
authorized by all requisite corporate actions on the part of such party; and

          5.1.3 This Agreement has been duly and validly executed and delivered by it and
constitutes a legal and binding obligation, enforceable against it in accordance
with its terms. 

     5.2 Emisphere Representations and Warranties. Emisphere represents and warrants that, as of the Effective Date: (a)
Emisphere owns, and has the right to assign, the entire right, title and
interest in and to the Assigned Patents; (b) there are no outstanding licenses,
liens, security interests, claims, options, or other grants or encumbrances with
respect to the Assigned Patents; (c) except for prosecution of the Assigned
Patents before the USPTO, no actions, suits, or claims have been filed or are
pending before any court or governmental agency challenging the validity or
enforceability of the Assigned Patents; (d) there are no reexamination, reissue,
or interference proceedings before the USPTO or any other patent office with
respect to the Assigned Patents; (e) with the exception of the Assigned Patents,
Emisphere is not the assignee of any pending patent applications or issued
patents, containing claims which would necessarily be infringed by practicing
the current claims in the Assigned Patents (i.e., as of the Effective Date), and
no assignments of any such applications or patents are owed to Emisphere by any
inventors or third parties. 

     5.3 Term
of Representations and Warranties. The
representations and warranties contained in Sections 5.1 and 5.2 of this
Agreement shall commence on the Effective Date, and expire on the six (6) year
anniversary thereof. Any claims for breach thereof must be tendered within such
six (6) year period. 

     5.4 Disclaimers. Except as expressly
stated in this Agreement, nothing shall be construed as: 

          5.4.1 constituting any representation or warranty that any claims in the
Assigned Patents will be granted by the relevant patent office(s); 

          5.4.2 obligating any party to defend, indemnify or hold harmless any other
party from any suits, actions, claims or causes of action alleging infringement
of, misappropriation of or violation of any third party’s intellectual property
rights; 

          5.4.3 imposing on any party an obligation to bring or prosecute actions or
suits against third parties for infringement; or 

          5.4.4 requiring any party to furnish or disclose to any other party any
technical or other information whatsoever. 

          5.5 Emisphere Covenant Not to Sue.
Emisphere covenants that it will not assert against MannKind, or MannKind’s
manufacturers, licensees, distributors or customers, any claim of direct or
indirect patent infringement arising from the manufacture, sale, import,
distribution or use of any diketopiperazine-based delivery system for
biologically active agents. Emisphere agrees that this covenant not to sue is
and shall be binding on its affiliates, successors, licensees and
assignees.

6. LIMITATION OF LIABILITY

     IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INDIRECT,
PUNITIVE, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR
ARISING OUT OF THIS AGREEMENT, OR FOR LOSS OF PROFITS, LOSS OF DATA, OR
ANY OTHER ECONOMIC LOSS, HOWEVER IT ARISES AND ON ANY THEORY OF LIABILITY,
WHETHER IN AN ACTION FOR CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING
NEGLIGENCE) OR OTHERWISE, WHETHER OR NOT EITHER PARTY OR THEIR AFFILIATES HAVE
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE AND NOTWITHSTANDING THE FAILURE
OF ESSENTIAL PURPOSE OF ANY REMEDY. NEITHER PARTY SHALL BE LIABLE UNDER THIS
AGREEMENT FOR ANY AMOUNT IN EXCESS OF THE CONSIDERATION PAID HEREUNDER BY
MANNKIND FOR ANY AND ALL CLAIMS FOR BREACH OR INDEMNIFICATION HEREUNDER IN THE
AGGREGATE. 

7. MISCELLANEOUS

     7.1
Notices.

          7.1.1 Any notice or other communication required or permitted to be given
hereunder shall be in writing and shall be delivered in person or sent by
certified mail, charges prepaid, or overnight courier, addressed as follows:

	To MannKind:  	    
	To Emisphere:  
	   
	MannKind
      Corporation  		Emisphere
      Technologies, Inc.  
	Attention: David
      Thomson, General  		Attention:
      General Counsel  
	Counsel  		240 Cedar Knolls
      Road  
	28903 North
      Avenue Paine  		Cedar Knolls,
      New Jersey 07927  
	Valencia,
      California 91355  		  
	 	 	 

          7.1.2 Any such notice or other communication shall be deemed to have been given
and received on the day on which it was personally delivered or, if mailed, on
the third (3rd) business day following the date of mailing or, if couriered
overnight, on the next following business day. 

          7.1.3 Either party may change its address for service at any time by giving
notice to the other party in accordance with this Section 8. 

     7.2 Entire
Agreement. This Agreement, together with the
agreements specifically contemplated herein or entered into or delivered in
connection herewith, constitutes the entire agreement between the parties with
respect to the subject matter hereof and supersedes all prior agreements. There
are no conditions, covenants, agreements, representations, warranties or other
provisions, express or implied, collateral, statutory or otherwise, relating to
the subject matter hereof except as herein provided or as provided in other
documents executed and delivered by the parties in connection herewith.

     7.3 Governing Law; Jurisdiction/Venue.
This agreement shall be construed, interpreted and enforced in accordance with,
and the respective rights and obligations of the parties
shall be governed by, the laws of the State of Delaware without reference to
choice of laws or conflict of laws principles. 

If Emisphere brings an action to
enforce or otherwise relating to this Agreement, it shall bring such action in
the state or federal courts located in Los Angeles County, California. If
MannKind brings an action to enforce or otherwise relating to this Agreement, it
shall bring such action in the state or federal courts located in Westchester
County, New York (or, if no federal court is located in Westchester County, the
federal court serving Westchester County). This choice of jurisdiction and venue
does not prevent either party from seeking injunctive relief with respect to a
violation of intellectual property rights or confidentiality obligations in any
appropriate jurisdiction. In any lawsuit arising out of or relating to this
Agreement, the prevailing party shall recover its reasonable costs and attorney
fees. 

     7.4 Severability. If any provision of this
Agreement is determined by a court of competent jurisdiction to be invalid,
illegal or unenforceable in any respect, such determination shall not impair or
affect the validity, legality or enforceability of the remaining provisions
hereof, and each provision is hereby declared to be separate, severable and
distinct. To the extent that any such provision is found to be invalid, illegal
or unenforceable, the parties hereto shall act in good faith to substitute for
such provision, to the extent possible, a new provision with content and purpose
as close as possible to the provision so determined to be invalid, illegal or
unenforceable. 

     7.5 Amendment and Waivers. No amendment or
waiver of any provision of this Agreement shall be binding on either party
unless consented to in writing by such party. No waiver of any provision of this
Agreement shall constitute a waiver of any other provision, and no waiver shall
constitute a continuing waiver unless otherwise provided. 

     7.6 Counterparts. This Agreement may be
executed in counterparts, each of which shall constitute an original and all of
which taken together shall constitute one and the same instrument. 

     7.7 Rules
of Construction. Unless the context otherwise
requires, in this Agreement: 

          7.7.1 The words “include,” “includes” and “including” means “include,”
“includes” or “including,” in each case, “without limitation;” 

          7.7.2 Reference to any agreement or other instrument referred to herein shall
mean such agreement or other instrument as amended, modified, replaced or
supplemented from time to time to the extent permitted by applicable provisions
thereof and by this Agreement; 

          7.7.3 The division of this Agreement into Sections, paragraphs, Schedules and
Exhibits and the insertion of headings and an index are for convenience of
reference only and shall not affect the construction or the interpretation of
this Agreement; 

          7.7.4 Unless otherwise specified herein, any reference in this Agreement to a
Section, paragraph, Schedule or Exhibit refers to the specified Section or
paragraph of or Schedule or Exhibit to this Agreement; 

          7.7.5 The terms “this Agreement,” “hereof,” “herein,” “hereunder” and similar
expressions refer to this Agreement and not to any particular part, Section,
paragraph or other provision hereof; 

          7.7.6 Reference to any statute shall be deemed to be a reference to such
statute as amended, reenacted or replaced from time to time; 

          7.7.7 Time periods within which a payment is to be made or any other action is
to be taken hereunder shall be calculated excluding the day on which the period
commences and including the day on which the period ends; and 

          7.7.8 The parties hereto acknowledge that their respective legal counsel have
reviewed and participated in settling the terms of this Agreement and that any
rule of construction to the effect that any ambiguity is to be resolved against
the drafting party, shall not be applicable in the interpretation of this
Agreement. 

     IN
WITNESS WHEREOF, the parties have agreed as of the date first written
above.

	EMISPHERE TECHNOLOGIES, INC.  	      	MANNKIND CORPORATION  
	  
	  
	Signature:  	/s/ Paul Lubetkin  		Signature:  	/s/ David Thomson  
		Paul
      Lubetkin  			David
      Thomson  
		Vice
      President, General  			Vice
      President, General  
		Counsel, and
      Corporate  			Counsel, and
      Corporate  
		Secretary  			Secretary  
	  
	Date:
      February 8, 2008  		Date:
      February 8, 2008 
  

SCHEDULE 1 – ASSIGNED PATENTS (INCLUDING
PATENT
APPLICATIONS) 

	TITLE 	U.S. PATENT (OR
      PATENT 	ISSUE/FILING
      DATE 
	  	APPLICATION)
      NO. 	  
	  Diketopiperazine-based
      delivery 	U.S. Patent No. 5,693,338 	Filed: 09/29/1994 
	 
      systems 	  	Issued: 12/02/1997 
	  Diketopiperazine-based
      delivery 	U.S. Patent No. 5,976,569 	Filed: 04/29/1997 
	 
      systems 	  	Issued: 11/02/1999 
	  Carbon-substituted 	U.S. Patent No. 6,331,318 	Filed: 09/30/1994 
	 
      diketopiperazine delivery systems 	  	Issued: 12/18/2001 
	  Carbon-substituted 	U.S. Patent No. 6,395,774 	Filed: 08/13/2001 
	 
      diketopiperazine delivery systems 	  	Issued: 05/28/2002 
	  Carbon-substituted 	U.S. Patent No. 6,663,898 	Filed: 04/19/2002 
	 
      diketopiperazine delivery systems 	  	Issued: 12/16/2003 
	  Carbon-substituted 	U.S. Patent No. 6,906,030 	Filed: 05/21/2003 
	 
      diketopiperazine delivery systems 	  	Issued: 06/14/2005 
	  Carbon-substituted 	U.S. Patent No. 7,276,534 	Filed: 02/18/2005 
	 
      diketopiperazine delivery systems 	  	Issued: 10/02/2007 
	  Carbon-substituted 	U.S. Patent Application No. 	Filed:
      09/21/2007 
	 
      diketopiperazine delivery systems 	11/859,506
    	Issued: n/a
    

 

 

Exhibit 1 – Patent Assignment Form
(attached) 

 

 

 

 

 

 

 

 

 

 

 

ASSIGNMENT OF PATENT
RIGHTS

     This
ASSIGNMENT OF PATENT RIGHTS, dated February 8, 2008 (this “Assignment”), is entered
into by Emisphere Technologies,
Inc., a Delaware corporation having a
business address at 240 Cedar Knolls Road, Cedar Knolls, New Jersey 07027
(“Assignor”), for the benefit of MannKind
Corporation, a Delaware corporation having a
business address at 28903 North Avenue Paine, Valencia, California 91355
(“Assignee”).

     WHEREAS, Assignor has agreed to sell
and assign, and the Assignee has agreed to buy and acquire all of Assignor’s
rights, title and interests in and to the letters patents and patent
applications set forth in Exhibit
A attached hereto (the “Assigned Patents and Patent Applications”).

     NOW,
THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged,
Assignor hereby assigns and transfers to Assignee any and all worldwide rights,
title and interests Assignor holds, or may hold, in and to the Assigned Patents
and Patent Applications, together with all rights derived therefrom, including
but not limited to the right to sue for and collect damages for past, present
and future infringement.

     Assignor
further agrees that, should additional or further documentation of the
assignment be required for whatever reason, Assignor will, without further
consideration, provide or execute such other information or documents as may be
necessary upon Assignee’s reasonable request.

     This
Assignment shall be binding on and shall inure to the benefit of, the parties
hereto and their respective successors and assigns. This Assignment will be
governed by, and construed in accordance with, the internal laws of the State of
Delaware applicable to contracts executed and performed entirely therein,
without regard to the principles of choice of law or conflicts or law of any
jurisdiction. If any term or other provision of this Assignment is invalid,
illegal or incapable of being enforced by any rule of law or public policy, all
other conditions and provisions of this Assignment will nevertheless remain in
full force and effect so long as the economic or legal substance of the
transactions contemplated hereby is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto will
negotiate in good faith to modify this Assignment so as to effect the original
intent of the parties as closely as possible in a mutually acceptable manner in
order that the transactions contemplated hereby be consummated as originally
contemplated to the greatest extent possible. This Assignment may be executed in
one or more counterparts, and by the different parties hereto in separate
counterparts, each of which when executed will be deemed to be an original but
all of which taken together will constitute one and the same agreement.

     IN
WITNESS WHEREOF, Assignor has caused this Assignment of Patent Rights to be
executed by its duly authorized representatives effective as of the date first
written above. 

		 
	 	Emisphere Technologies, Inc.  
			  
			  
		By:  	/s/ Paul
      Lubetkin  
			Name: Paul
      Lubetkin  
			Title: V.P,
      General Counsel, and  
			Secretary  

 

STATE OF NEW JERSEY 

COUNTY OF MORRIS 

     On this
11th day of February, 2008, before me, a Notary Public in and for
said State, personally appeared Paul Lubetkin personally known to me (or proved
to me on the basis of satisfactory evidence) to be the person(s) whose names(s)
is/are subscribed to the within instrument and acknowledged to me that
he/she/they executed the same in his/her/their authorized capacity(ies), and
that by his/her/their signature(s) on the instrument the person(s), or entity
upon behalf of which the person(s) acted, executed the instrument. 

WITNESS, my hand and official seal.

		 
		/s/ Francis
      Van Ness  
		Notary
      Public  

EXHIBIT A

ASSIGNED PATENTS AND PATENT
APPLICATIONS

	TITLE 	U.S. PATENT (OR
      PATENT 	ISSUE/FILING
      DATE 
	  	APPLICATION)
      NO. 	  
	  Diketopiperazine-based
      delivery 	U.S. Patent No. 5,693,338 	Filed:
      09/29/1994 
	 
      systems 	 	Issued:
      12/02/1997 
	  Diketopiperazine-based
      delivery 	U.S. Patent No. 5,976,569 	Filed:
      04/29/1997 
	 
      systems 	  	Issued:
      11/02/1999 
	  Carbon-substituted 	U.S. Patent No. 6,331,318 	Filed:
      09/30/1994 
	 
      diketopiperazine delivery systems 	  	Issued:
      12/18/2001 
	  Carbon-substituted 	U.S. Patent No. 6,395,774 	Filed:
      08/13/2001 
	 
      diketopiperazine delivery systems 	  	Issued:
      05/28/2002 
	  Carbon-substituted 	U.S. Patent No. 6,663,898 	Filed:
      04/19/2002 
	 
      diketopiperazine delivery systems 	  	Issued:
      12/16/2003 
	  Carbon-substituted 	U.S. Patent No. 6,906,030 	Filed:
      05/21/2003 
	 
      diketopiperazine delivery systems 	  	Issued:
      06/14/2005 
	  Carbon-substituted 	U.S. Patent No. 7,276,534 	Filed:
      02/18/2005 
	 
      diketopiperazine delivery systems 	  	Issued:
      10/02/2007 
	  Carbon-substituted 	U.S. Patent Application No. 	Filed:
      09/21/2007 
	 
      diketopiperazine delivery systems 	11/859,506
    	Issued: n/a

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]